Is natalizumab a breakthrough in the treatment of multiple sclerosis?

  title={Is natalizumab a breakthrough in the treatment of multiple sclerosis?},
  author={S. Doggrell},
  journal={Expert Opinion on Pharmacotherapy},
  pages={1001 - 999}
  • S. Doggrell
  • Published 2003
  • Medicine
  • Expert Opinion on Pharmacotherapy
  • In patients with either relapsing-remitting or secondary-progressive multiple sclerosis, there were fewer new lesions/patient with natalizumab (0.7 and 1.1 with natalizumab 3 and 6 mg/kg every 28 days, respectively) than in the placebo group (9.6 new lesions/patient) over 6 months. There were also fewer relapses in the natalizumab groups than the placebo group. However, there were no changes in the Expanded Disability Status Scale scores in any of the groups. Natalizumab was well-tolerated… CONTINUE READING
    5 Citations

    Topics from this paper


    A controlled trial of natalizumab for relapsing multiple sclerosis.
    • 1,151
    • PDF
    Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review.
    • 86
    • PDF
    Interferons in relapsing remitting multiple sclerosis: a systematic review
    • 295
    • PDF
    The effect of anti-α4 integrin antibody on brain lesion activity in MS
    • 279
    A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis.
    • 50
    • Highly Influential
    Rating neurologic impairment in multiple sclerosis
    • 11,799
    • PDF
    A monoclonal antibody to α4 integrin suppresses and reverses active experimental allergic encephalomyelitis
    • 187